Year: 2019
Type: editorial
Abstract: Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered 'undruggable'. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.
Source: British Journal of Cancer
Authors: Colin R. Lindsay, Fiona H. Blackhall
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,367
OpenAlex ID: W2955131133
